• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>DRS

DRS

  1. All
  2. 3rd Party
  3. Investing
  1. Wi-Fi Calling Stymies Residential Femtocells but Enterprise Leads the Femtocell Market to US$800 Million, Says ABI Research

    Wi-Fi Calling Stymies Residential Femtocells but Enterprise Leads the Femtocell Market to US$800 Million, Says ABI Research

  2. Columbia Laboratories Begins Trading as Juniper Pharmaceuticals (JNP)

    Columbia Laboratories Begins Trading as Juniper Pharmaceuticals (JNP)

  3. Naia Limited Appoints Three World-Class Business and Healthcare Thought Leaders to Its Business Advisory Board

    Naia Limited Appoints Three World-Class Business and Healthcare Thought Leaders to Its Business Advisory Board

  4. Columbia Laboratories, Inc. to Become Juniper Pharmaceuticals, Inc.

    Columbia Laboratories, Inc. to Become Juniper Pharmaceuticals, Inc.

  5. RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea

    RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea

  6. Roger Ibbotson, Benoit Mandelbrot, and George Cooper

    Our distinguished economics panel debates the value of current risk models.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.